Table 4.
Patient no. | Indication for antibiotics | Drugs | Days after gene therapy at start of antibiotic treatment | Baseline neutrophil count, cells/μL* | Neutrophil nadir, cells/μL | Time to neutrophil nadir, days | Time to recovery of ANC to > 500 cells/μL without G-CSF, d |
---|---|---|---|---|---|---|---|
ADA10 | Catheter exit site infection | Oxacillin, vancomycin | 84 | 1290 | 270 | 20 | 74 |
ADA14 | Surgical prophylaxis | Cefazolin | 361 | 3677 | 764 | 1 | NA |
ADA16 | S epidermidis bacteremia | Vancomycin; TMP/SFX, fluconazole acyclovir, rifampin, ethambutol, isoniazid, clarithromycin | Treatment started prior to gene therapy | 3023 | 449 | 31 | 37 |
Pneumonia | Ceftriaxone, amoxicillin/clavulanic acid, azithromycin | 63 | 2858 | 373 | 14 | 15 | |
Pneumonia/E coli bacteremia | Meropenem, amoxicillin/clavulanic acid azithromycin | 546 | 4620 | 387 | 11 | 37 | |
Otitis media | Levofloxacin, Linezolid | 1463 | 1110 | 680 | 15 | NA | |
Fever | Azithromycin | 1487 | 3490 | 490 | 2 | 6 |
TMP/SFX indicates trimethoprim/sulfamethoxazole; and NA, not applicable.
Neutrophil count immediately before antibiotic treatment.